Services on Demand
- Cited by SciELO
- Access statistics
- Cited by Google
- Similars in SciELO
- Similars in Google
On-line version ISSN 0718-2724
Journal of Technology Management & Innovation vol.4 no.2 Santiago July 2009
J. Technol. Manag. Innov. 2009, Volume 4, Issue 2
Development of a Biomedical Innovation Economy-Panama
Markus Dettenhofer 1, Nora Hampl 2
1 Department of Genetics, Harvard Medical School. 77 Avenue Louis Pasteur-NRB356. Boston, MA 02115, USA. Tel: +16174327578. E-mail: email@example.com
2 Davis Center and Department of Slavic Languages and Literatures, Harvard University, 12 Quincy Street-Barker Center #340. Cambridge, MA 02138, USA. Tel: +16174968161. E-mail: firstname.lastname@example.org
In this study we consider the progress toward the development of innovation incubators within the Central American country of Panama. We attempt to identify the extent to which Panama, as a developing country with a small market size, has recognized the importance of technology and innovation in its efforts to build a sustainable economy. We examined the "Triple Helix" government-academia-industry model (Etzkowitz, 2008), and applied it to the bioscience sector, while also incorporating the role of foreign collaborators. By reinforcing and maintaining synergies among all stakeholders, while also concentrating resources in the areas of strengths and increasing R&D expenditures, Panama could become a key regional player in the bioscience sector. Examples of cooperative research innovation are highlighted, and suggestions are made to enhance their commercialization potential.
Keywords: panama; bioscience; development; synergistic coordination.
Independence gained from Gran Columbia was realized in 1903, but one could argue that the history of modern Panama started more recently. Two recent events significantly shaped present day Panama, the United States invasion of 1989, and the hand-over by the United States of the canal and with it billions of dollars worth of land and infrastructure (Pérez, 2000). The withdrawal of the remaining US military presence in the year 2000 allowed Panama to gain full sovereignty of its territories, and make independent decisions about the management of the Canal and the surrounding land. Today, Panama sees itself as an important logistical hub, keen on developing a foreign policy agenda with a number of global players. Even after the US-led invasion and disputes over military base rights, Panamanians retain a favorable view of the United States, and seek to strengthen their trading ties (Furlong, 2000). The relationship with Japan as the second largest trading partner is likely to continue as Panama looks to increase importation of Japanese technological goods. Other Asians countries such as China, Taiwan and Korea are increasing their level of investment and trade with Panama. The Colon Free Trade Zone is the largest of its kind in the Western Hemisphere, as it handles more than US$14 billion in imports and re-exports each year.
Today's economy is largely based on transportation and logistics, financials, insurance, exportation of goods and services, and tourism comprising more than 80% of its productive output. Panama has recently enjoyed a period of substantial economic stability, with annual GDP growth of more than 8% over the last three years (U.S. Dept. of State, 2009). In an effort to build a diversified economy, a national strategy has been formulated to encourage science, technology and innovation. To this end, the government of Panama has prioritized science, technology and innovation for its long term growth. The presence of good infrastructure including transportation, electrical power generation, clean water, and internet connectivity within Panama City, and its central geographic location between North and South America, make it an attractive location for foreign investment. However, weaknesses have been acknowledged in the areas of innovation and higher education training (Cimoli, 2005). Many developing countries have recognized the importance of technology and innovation in their efforts to build sustainable economies. In this study we examined the potential opportunities for bioscience innovations and the barriers that might exist.
1. Data Collection
To get a more complete perspective of the innovative bioscience space in Panama, three main data sources were utilized for this study. We conducted personal interviews with individuals from the government, academia, technology park and private companies. Also, questionnaires were distributed regarding organizational interconnectivity and support for commercialization in Panama. Finally, traditional reference data were utilized to provide historical context and analysis within this space.
2. Economic Agents
Private companies or institutes that undertake research and development to generate products or services play an important role in a knowledge-based economy (Powers & Powers, 1988). They serve not only to sell the goods and services of their labor force, but also to employ graduates of the universities. Locally or regionally generated diagnostic services, medicines and medical devices, as well as improvement in agricultural technologies, may present an attractive economic alternative to the importation of such products from large developed countries. For the bioscience sectors, health and agriculture-related products and services additionally contribute to the improvement in quality of life for the population (Cooke, 2007). The decision process for students in choosing an area of concentration is influenced not only by their intrinsic interests, but also by their exposure to external influences. The local presence of economic agents known to employ students impacts their choice of study.
Although there are a hand-full of innovative bioscience companies in Panama, only a few are a result of solely Panamanian innovation efforts. Several Clinical Research Organizations (CROs) have operations in Panama and they include: Health Research International of the University of South Florida, Quintiles, a CRO based in North Carolina, and LaTAM Mo Clinical Research, a US-Columbian venture. The Institute of Advanced Scientific Investigations and High Technology Services (INDICASAT) operates as a non-profit government research institute concentrating on medical-related local issues, such as infectious diseases. INDICASAT also serves as a regional CRO for pharmaceutical companies (eg. Glaxo Smith Kline), in human papilloma virus vaccines. The current trend towards establishment of clinical trials organizations within Panama is likely to continue due to the skilled medical personnel, a track record of previous FDA approved clinical trials, and reduced exposure to medication among the population as compared with developed countries.
In addition to CROs, several small international bioscience-focused companies have a presence in Panama. The Venezuela-Japanese-American joint-venture nanotech company, Nano Dispersion Technologies, develops dispersion fluids-breaking particles to a nanometric size. This technology may be applied to multiple industries ranging from oil and bio-fuels to cosmetics. With passage of the recent laws allowing research and therapeutic treatment using stem cells, two foreign companies have developed a presence within Panama. MediStem, which has facilities in the US and Costa Rica, focuses on discovery, development and commercialization of technologies related to adult stem cell extraction and manipulation for use in treating inflammatory and degenerative diseases. The Chinese company Beike, which also has operations in Thailand and Europe, has treated more than 2000 patients with umbilical cord stem cell injection principally for neurodegenerative diseases. Natural Control Corporation is an agriculture and insecticide company, which has been in existence for 40 years in Columbia, and now also has a presence in Panama. The business focus is on the improvement of output of mainly agricultural products, which have yielded revenues with the government as its principle client.
As bioscience innovation can be very capital intensive, it has the potential of not only large financial rewards but also the development of societal good (Cooke, 2007). This being the case, a large risk of failure exists for overly ambitious projects which are not gauged appropriately. Large multinational companies will take a calculated risk of entry based on a variety of factors such as tax incentives, trade tariffs, existing skilled labor force, infrastructure, and regional demand for their goods and services. Market entry for small organizations with little capital will need to consider these points, but work from the perspective of a short-term revenue model. The success of economic agents will rely on the ability of organizations to capitalize on local and regional strengths and build stakeholder interest in local and foreign markets (Brown & Duguid, 2002; Gal, 2003). Building a local presence in addition to establishing foreign partnerships or collaborations with universities and private companies will reduce some risks inherent in starting of new ventures. Also, the importation of technical expertise, even on a temporary basis, will be critical to adequately train local students to become future employees. This will have the added advantage of rapid adaptation of innovative technologies and become a starting point for increased funding from international funding agencies. For a country such as Panama with a total market size of 3.3 million people, economic agents will be wise to pitch their goods and services to address local needs but also the global market. For example, services such as DNA-based disease diagnosis may find an adequate local market for their services, but non-repeat use therapies may find the Panamanian market too small for sustainability. Nevertheless, even those bioscience innovation projects that consider the larger regional market and near-term revenue have the opportunity for sustainability.
A great promise for bioscience-related enterprise generation within Panama revolves around clinical trial activities. The establishment of a standardized health care facilities and low cost of medical care have encouraged CROs to enter emerging markets. Central and South America combined form a regional block with a total population of 562 million. From this perspective the region will become of greater importance to the pharmaceutical industry. From the standpoint of clinical trials, low cost is a driving force, as are the relative naïve levels of exposure to medicines by the population at large (Shah, 2003; Getz, 2006). For countries such as Panama, the overall perception of clinical trial quality by regulatory agencies such as the FDA remains to be determined.
Emphasis in Panama has been placed on increasing the enrollment of students in university level education. From 1970 to 2000, university level education among scientific and technologically active employees has grown from 12% to 20% during this time frame (Villavicencio and Chiapa, 2006), yet only 0.5% of the economically active population is involved in science and technology as a profession. Traditionally, academic interests in biosciences have not been strong, with the exception of medicine and forensics. Given the recognized strengths of Panama's biologically-rich environment and the growing sector engaged in medical services, mechanisms are being put in place to increase the student population trained in these areas of specialization.
The University of Panama (UP) which was founded in 1935, has a student population of approximately 74,000. UP being the largest university system in the country has developed a number of bioscience related centers, which serve as areas of study concentration. The UP offers a Master's degree program in biological sciences with four concentrations: 1) genetics and molecular biology, 2) zoology, 3) plants science, and 4) marine biology. At present UP does not offer a PhD program in biological sciences but instead sends promising students to conduct thesis research at the University of Granada in Spain. There is a clear recognition among the faculty of the importance of commercialization of discovery. UP scientists continue to conduct experimental analysis of plant extracts from the surrounding jungles for biological activities of therapeutic benefit. Funding has been granted through the NIH for these studies, and collaborations with US universities continue. Patent protection for these discoveries has primarily been granted through the United States Patent and Trademark Office. The General Office for Registration of Industrial Property (DIGERPI) handles local intellectual property issues and falls under the guidance of the Ministry of Commerce and Industry.
The UP in an effort to facilitate commercialization of discovery has newly created the office of Transference of Research Results (OTRI in Spanish) in the City of Knowledge. This office functions as a link between UP and private sector companies. In this arrangement the University offers guidance with respect to proper economic incentives for the scientists involved in advancing their discoveries to commercialization. Also, UP has organized and participated in several workshops on intellectual property and patents, and recently, it has set up a database containing information regarding patents and intellectual property to assist researchers.
Other institutions in Panama have developed programs in biosciences. The Technological University of Panama offers a biotechnology study program with applications to the agricultural industry.
The ministry of science and technology (SENACYT) has taken a very proactive role in the encouragement and development of a knowledge-based sector. It is well recognized that the economic competitiveness of a nation is linked with knowledge development (Arocena & Sutz, 2000). To this effect, SENACYT has coordinated the formulation of a National Strategic Plan for the Development of Science, Technology and Innovation for the years 2006-2010. The aim is to provide a framework to guide the growth of a knowledge-based sector in Panama with respect to an array of science-related industries. As for the biosciences, recommended steps of action have been brought forth and include the formation of a national bioscience commission to provide guidance and policy oversight with the aim of strengthening capacity in technology and human resources to support sustainable development. Additional recommendations include the formation of a funding agency for biosciences, the development of human resources to meet the science and technology demands of the country, and further development of a five-year plan to broaden research in biosciences.
To date, SENACYT has already incorporated a number of aspects of the Strategic Plan. Since 2004, SENACYT has funded 280 scholarships ranging from the Bachelors degree level through to the PhD and Post-doctoral level. Of these, approximately 150 were for doctoral or post-doctoral level studies in foreign universities. In 2008 alone, Panama has invested $8 million in scholarships. Scientific funding has also been made available for research in areas including biosciences, agriculture, tourism, logistics and transportation through an open granting process that is reviewed by an international board, and where emphasis is being placed on collaborative efforts that tie into the strengths of the country. The Open Calls or grants are available to both public and private entities. SENACYT has directed over $10M in public funding toward projects and activities in innovation as well as R&D where both the private and governmental sector have been involved in conjunction with international collaborators. Although government constitutes the largest domestic funding source, financing from foreign sources represented 71% of all R&D spending in 2002 (OECD Paris, 2004). Additionally, the National Research System (Sistema Nacional de Investigacion-SNI) was created in December 14, 2007 (Law 54), with the objective of providing policy direction and promoting scientific and technological research through economic incentives.
The favorable Panamanian tax incentives, high-level of computer connectivity and strong economic growth imply that basic elements to encourage growth in technological output are present. To this effect, the development of the Technology Park within the City of Knowledge lends itself for innovation clustering. The presence of international NGOs and collaborative education programs with Louisiana State University and Florida State University may be a base for capacity building. However, improvements are needed in local science education and research training, strengthening public-private collaborations, intellectual property filings and job creation.
As the operating budget for INDICASAT is supported by the government, it has several revenue-generating programs in place that consist of contracts or collaborative agreements with foreign universities or companies. One of INDICASAT's collaborations links efforts of the University of Panama and the Smithsonian Tropical Research Institute to prospect for biologically active factors from natural sources, which falls under the International Cooperative Biodiversity Groups (ICBG) program. Bioassays are used to test extracts for potential therapeutic relevance, such as inhibition of infectious disease replication or as anti-cancer agents. Further preclinical testing of extracts is performed in collaboration with universities in the United States. INDICASAT is staffed by Panamanians, as well as foreign scientists trained either in foreign or local universities.
The public health institution, Gorgas Commemorative Institute of Health Studies (Instituto Conmemorativo Gorgas de Estudios de la Salud: República de Panama), founded in 1921 , performs scientific research in health, epidemiology, and environment. With a generous grant from the Global Fund, Gorgas is building a state-of-the-art facility to help develop a biomedical training program and reference diagnostic laboratory for the region. Gorgas additionally collaborates with Johns Hopkins Medical International in the areas of HIV, women's health, and medical and public health education, as it trains local talent in biomedical, laboratory, clinical and epidemiologic research. In operation since 2006, the Hospital Punta Pacifica is currently being managed by Johns Hopkins Medicine International. Besides providing clinical and diagnostic care, it also offers training opportunities for physicians.
The Smithsonian Institute for Tropical Research (STRI), which is a US government agency based in Panama, is a world class research institute which focuses on evolutionary biology and ecology. Its involvement in basic ecological research and characterization of plant and animal species diversity, set the groundwork for the ICBG program mentioned above. This program has received international funding from the National Institutes of Health, the US National Science Foundation, and the US Department of Agriculture (Rosenthal and Katz, 2004; Kursar, 2007). The STRI, which employs approximately 40 permanent international staff scientists, conducts some of the ICBG research jointly with UP and INDICASAT.
5. Synergistic Coordination
To develop a knowledge-based bioscience sector in a small market such as Panama, a synergistic coordination among various stakeholders will be needed to strengthen the sector as a whole (Figure 1). Sectors based on knowledge-driven innovation and commercialization of discoveries as a means of stimulating economic growth, have been characterized in the "Triple Helix" model (Etzkowitz, 2008). This model incorporates policy-driven initiatives that promote the interaction between government, academia, and industry. The government of Panama plays a significant role in making available the regulatory guidance, infrastructure, and public financing for innovative projects. The greatest benefactors thus far have been academic and non-profit research institutes, but private companies with innovative programs may benefit as well. While Panamanian universities place emphasis on teaching, they are constrained with regard to pushing innovative research agendas forward. The importance of training students to become productive members of the knowledge-based labor force is of great interest when trying to encourage bioscience development to prosper (Wemmer, 1993). Companies can aid in this process by incorporating promising students into internship programs to prepare them for careers in the private sector. Because a majority of bioscience R&D-dependent businesses have long cycles before they generate revenues, they tend to be initially dependent on private financing groups. A return on investment in bioscience innovation projects has traditionally come from buy-outs, stock exchange listings, or large-scale growth through sales of the organization's goods and services (Hall, 2002). When innovative enterprises seek private financing, two issues have to be addressed above all: a reasonable chance of success and a viable exit strategy for the investment. Once successful precedents are created on the market, financiers become more involved, and the sector will grow more rapidly. An increase in science capacity should also lead to job creation and generation of new products, which will ultimately serve the government's interests in growing the economy.